This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Clinical Experience -
Long-term effectiveness of luteinizing hormone-releasing
hormone agonist or antiandrogen monotherapy in elderly men with
localized prostate cancer (T1-2) : a retrospective study
Rupesh Raina1,2, Geetu
Pahalajani1, Ashok Agarwal1, Craig
Zippe1
1Department of Medicine and Pediatrics, Metrohealth Medical Center (Case School of Medicine), Cleveland,
Ohio 44109, USA
2Glickman Urological Institute, Cleveland Clinic Foundation at Mary Mount, Cleveland Clinic Foundation, Ohio
44125, USA
Abstract
Aim: To evaluate the long-term effectiveness, side effects and compliance rates of two types of drugs (luteinizing
hormone-releasing hormone [LHRH] agonist and antiandrogen) that were used individually to treat patients with
localized prostate cancer (T1_2) at our
institution. Methods: Ninety-seven patients who were diagnosed in the period
from April 1997 to January 2000 as having clinically localized prostate cancer (T1_2) received either LHRH agonist
(leuprolide acetate 7.5 mg/month) monotherapy (group 1,
n = 62) or antiandrogen monotherapy (group 2,
n = 35; 18 received bicalutamide 50 mg q.d., 13 received nilutamide 150 mg t.i.d. and 4 received flutamide 250 mg t.i.d.). The
mean age in both groups was 76 years. Results:
The mean follow-up time was (50.8 ± 8.5) months in group 1 and
(43.1 ± 2.2) months in group 2. Prostate-specific antigen (PSA) levels rose in only 1 of the 62 patients (1.6%) in
group 1, and in 20 of the 35 patients (57.1%) in group 2. In group 2, 10 of the 20 patients (50 %) with increasing PSA
levels were treated with LHRH salvage therapy, and eight (80%) responded. Hot flashes (54.8%) and lethargy
(41.9%) were the most common side effects in group 1. In contrast, nipple-tenderness
(40%) and light-dark adaptation (17.1%) were more often seen in group 2. Only 1 of the 62 patients (1.6%) in group 1 switched to another medication
because of adverse side effects; whereas 8 of the 35 patients (22.9%) in group 2 did so.
Conclusion: Unlike antiandrogen monotherapy, LHRH agonist monotherapy provided long-term durable control of localized prostate
cancer (T1-2). It can also be an effective treatment option for patients whose disease failed to respond to antiandrogen
monotherapy. The limitations of our study are the lack of health outcomes analysis and a small sample
size. (Asian J Androl 2007 Mar; 9: 253_258)
Keywords: localized prostate cancer; antiandrogen;
prostate-specific antigen; luteinizing hormone-releasing hormone agonist; androgen;
ablation; monotherapy
Correspondence to: Rupesh Raina, M.D., Department of Medicine and Pediatrics, Metrohealth Medical Center (Case School of Medicine),
2500 MetroHealth Drive, Cleveland, Ohio 44109, USA.
Tel: +1-440-887-1663 / +1-216-778-2882 Fax: +1-216-778-1384
E-mail: rraina@metrohealth.org
Received 2004-07-19 Accepted 2005-05-08
DOI: 10.1111/j.1745-7262.2007.00074.x
1 Introduction
Prostate cancer is the most common cancer in men
and the second leading cause of cancer-related male
deaths in western countries [1]. The incidence of
prostate cancer is rising, partly because the growth of public
awareness of the disease has increased the number of
men being screened for it [2_3]. In turn, more men are
presenting with localized prostate cancer than ever
before [3_5].
In addition, the life expectancy of the American man
is increasing. The averagely 65-year-old men can now
expect to live additional 17 to 20 years compared to mean
age of 10 years after diagnosis of prostate cancer [6].
As a result, the incidence of prostate cancer in the
elderly has dramatically increased. At the same time, many
elderly patients with prostate cancer who in the past would
have died of comorbidities (e.g. ischemic cardiac
disease or hypertensive cerebrovascular accidents) while
under observation no longer do so because of better
medical care. Thus, we are now faced with the issue of
how to best treat elderly patients in order to prevent
metastatic prostate cancer death.
Treatment options for patients older than 70 years
with localized prostate cancer remain controversial.
Current options include radical surgery [7], radiation therapy
[8], expectant management (observation) [9, 10] and
hormone therapy [9]. Because many elderly men are
ineligible or unsuitable candidates for definitive radiation
therapy or radical prostatectomy, or are unwilling to
undergo an observation protocol, hormone therapy is now
being looked at more closely.
In 1941, Huggins et al. [7] were the first to
pro-pose hormone therapy for the management of advanced
prostate cancer. However, there are few data on the use
of hormonal treatment to control localized prostate
cancer. Small tumors are highly sensitive to
androgen deprivation, suggesting that androgen blockade
could be given at the early stages of prostate cancer
[11]. Aggressive definitive treatment may result in a lower
cancer-specific mortality at 10 years after diagnosis of
prostate cancer, but the difference between aggressive
and hormonal treatments appears to be small. Finally,
patients between the ages of 65 years and 75 years with
clinically localized, well-differentiated prostate cancer
who have been treated with delayed endocrine therapy
incur no greater loss of life expectancy than the general
population [12].
Because of the limited data that suggest that
hormone therapy might be an effective treatment for
loca-lized prostate cancer and the well-documented approach
of using a luteinizing hormone-releasing hormone (LHRH)
agonist or antiandrogen monotherapy for metastatic
prostate disease, we sought to compare the effectiveness,
side effects, and patient compliance rates of these two
types of drugs in patients with localized prostate cancer
(clinical stages T1 and T2, T1-2) who were ineligible for
definitive local therapy (radical surgery and radiation
therapy) or unwilling to undergo observation. Although
other studies have evaluated the effects of these drugs in
patients with T3 tumors, this is the first study to
compare these drugs in patients with clinical T1_2 prostate
cancer.
2 Materials and methods
2.1 Patients and treatments
Our study consisted of 97 patients diagnosed as
having localized prostate cancer (T1_2) and were treated
with LHRH agonist or antiandrogen at our tertiary care
institution. Diagnosis was based on a digital rectal
examination (DRE), a total PSA level and negative bone
scans. Of the 97 patients, 62 (group 1) were placed on the
LHRH agonist leuprolide (22.5 mg for 3 months or 7.5 mg
for 1 month). In the remaining 35 patients (group 2), 18
received bicalutamide (50 mg q.d.), 13 received nilutamide
(50 mg t.i.d.), and four received flutamide (250 mg t.i.d.).
The patients' charts were reviewed for the
following data: age at the beginning of treatment, pre- and
post-treatment PSA levels, Gleason score, tumor stage,
treatment side effects, PSA nadir, tolerance (whether or not
the patient switched to another medication) and
follow-up time. PSA nadir was taken to mean the failure of
treatment once the PSA levels rise more than 0.5 ng/mL.
All patients included in the study were from the single
urologists' (Dr Craig D Zippe) series. Data collection
and analysis were carried out by the principal
investigator (Dr Rupesh Raina). There were no mortalities caused
by progression of the disease reported during the study
period. Most of the patients were switched to hormonal
therapy from androgens.
2.2 Statistical analysis
Comparisons between groups 1 and 2, and among patients within group 2, were performed using
the Wilcoxon rank sum test or Fisher's exact test as appropriate. The
results of the former test are presented as median and
interquartile ranges and those of the latter were presented
as percentages. All analyses were performed with the
SAS statistical software package (SAS Institute, Cary,
NC, USA). P < 0.05 was considered significant.
3 Results
Baseline patient characteristics (mean age at the
beginning of treatment, mean follow-up time, mean initial
PSA and mean Gleason score) are presented in Table 1.
There were no statistically significant differences between
the two groups.
Table 1 shows the mean PSA nadir as well as other
biochemical characteristics and the number of patients
who switched medications (patient tolerance). Not only
was the mean PSA nadir lower in group 1, but it also
occurred more quickly (with a mean of 3 months
vs. 23 months for group 2). Moreover, only one patient in group
1 experienced PSA progression, and only one patient in
this group switched to another medication.
Table 2 lists the side effects associated with each
medication. Hot flashes (54.8%) and lethargy (41.9%)
were the most common side effects of LHRH agonist therapy. The one patient in group 1 who switched
medication to antiandrogen monotherapy did so because of
persistent hot flashes. In contrast, no patients in
group 2 experienced these effects. However, nipple-tenderness
(40%) and light-dark adaptation (17.1%) was experienced
significantly more often by group 2 patients. Patients
who experienced the side effect of reduced light-dark
adaptation received nilutamide.
In group 2, 20 of the 35 patients (57.1%) broke
through their PSA nadir. Ten of these patients were
switched to the LHRH agonist therapy, where upon eight
responded (a successful LHRH rescue was defined as
PSA nadir < 0.5) and two did not. The other 10 patients
who showed PSA progression, either continued on antiandrogen therapy
(n = 5), chose observation (n = 1), chose to have a radical prostatectomy
(n = 1), or died of comorbid diseases
(n = 3). We compared the baseline characteristics of those patients showing PSA
progression while on antiandrogen monotherapy with those who
did not. These results are displayed in Table 3. Both the
groups had an equivalent frequency of follow-up. The
mean follow-up time, initial PSA, and PSA nadir were all
higher in the patients showing PSA progression. However, only follow-up time was significantly
different between the two groups.
Finally, we analyzed the characteristics of the
patients who did not respond to antiandrogen monotherapy
and who received LHRH salvage therapy based on their
initial PSA levels. Patients with low initial PSA levels
(< 30 ng/dL, n = 6) responded better to LHRH salvage
therapy (100 %) than those with high initial PSA levels
(³ 30 ng/dL, n = 4) (25%). These results are shown in
Table 4, where it can be seen that the mean PSA nadir
while on monotherapy was higher in the poor
responders (P < 0.05).
4 Discussion
As can be seen, the LHRH agonist therapy controlled
PSA progression better than antiandrogen monotherapy.
One of the most important aspects of this study (as it
related to the effectiveness of the two drugs) was that
only 1 of 62 patients (1.6%) taking LHRH agonist therapy
broke through his PSA, as opposed to 20 of 35 patients
(57.1%) taking the antiandrogen monotherapy.
These results may have been different if higher doses of bicalutamide
had been administered, a practice that has become
increasingly common. Indeed, literature have shown 150 mg
of bicalutamide to be more efficacious than the 50 mg
which was administered in this study.
The side effects of LHRH agonist therapy in the
treatment of prostate cancer have been well described,
particularly hot flashes and impotence [13_15]. In addition,
lethargy, asthenia and bone demineralization (osteoporosis)
have also been reported as side effects of chronic use of
LHRH agonist therapy [9_12]. The current interest in
intermittent androgen ablation protocols was stimulated
by the issue of side effects [10] .
Flutamide was the first nonsteroidal antiandrogen used
to treat prostate cancer [11]. Its side effects include
diarrhea, gastrointestinal discomfort and gynecomastia; these
have been shown to occur in up to 15% of the patients
withdrawing from treatment [16]. Similar to flutamide,
the most frequent side effects of bicalutamide include
hot flashes, gynecomastia, breast tenderness and diarrhea.
In general, bicalutamide has been reported to result in
fewer gastrointestinal symptoms [11]. Nilutamide,
another nonsteroidal antiandrogen, appears to have a
similar effect on prostate cancer as flutamide [11]. Reported
side effects include visual adaptation problems (light-dark
adaptation), alcohol intolerance, and occasional severe
pulmonary toxicity [11, 17]. In comparison to the other
two antiandrogens, nilutamide has fewer gastrointestinal
side effects. The incidence of reduced light-dark
adaptation in 10%_30% of patients is the primary reason for
discontinuation of this drug.
In our study, the most common side effects were
hot flashes and lethargy in the patients on LHRH agonist,
and nipple tenderness and light-dark adaptation in the
patients on antiandrogen monotherapy. Interestingly, one
patient in group 1 experienced breast tenderness, and he
was placed on a 2-month course of tamoxifen, which
resolved the pain. Almost one half (16/35) of the
patients treated with antiandrogen monotherapy experienced
side effects, with 8 of the 16 patients switching to
another antiandrogen. Finally, recent quality of life studies
have demonstrated that antiandrogen monotherapy allows
patients to retain greater physical capacity and sexual
interest than LHRH agonists [15]. Consistent with these
findings, our study shows that 41.9% of patients on LHRH
agonist reported lethargy, whereas no patient on antiandrogen monotherapy complained of fatigue. Data
on sexual interest and sexual function were not included
in this study because accurate information regarding the
pre-treatment status of the patients' erections was largely
unavailable.
The role of antiandrogen monotherapy in localized
prostate cancer is evolving.
It would be beneficial to identify risk factors that
predict patients who are likely to break through their PSA
nadir. However, our results show no difference between
the baseline characteristics of those whose PSA levels
progressed while on antiandrogen monotherapy and those
whose PSA levels did not. However, these results may
have been overstatement due to the fact that the group
with PSA progression had a longer mean follow-up time.
Androgen insensitivity is a major problem
associated with the hormonal control of prostate cancer.
Patients who show PSA progression on antiandrogen monotherapy can often be rescued by the addition of an
LHRH agonist. In the small population of patients in the
present study who were placed on LHRH agonist salvage therapy
(n = 10), nine responded and one did not.
We analyzed the characteristics of these patients to
determine the factors that might possibly put patients at
risk of being insensitive to LHRH salvage therapy
following progression on antiandrogens. Our results
indicate that patients with higher initial PSA values showed a
poorer response to LHRH salvage therapy. In addition,
the PSA nadir of a patient, while on monotherapy, may
be predictive of LHRH salvage therapy failure because
the PSA nadir was significantly higher in the group
showing poor response to the LHRH agonist. The elevated
PSA nadir likely reflects progression to androgen-independence. We believe these data may be clinically
important enough to warrant further investigation.
Our results are consistent with the findings of other
researchers in that LHRH agonist therapy has been found
to be more effective than antiandrogen monotherapy [18].
However, antiandrogen monotherapy may still play a role
in the treatment of localized prostate cancer in two ways:
1) by acting as a short-term suppressant while the
patient undergoes treatment for other medical conditions;
or 2) by acting as step therapy for a patient who is
sensitive to quality of life issues (i.e. potency or lethargy)
and who would prefer to reduce the time required on
LHRH agonist therapy. It should be emphasized that
patients on antiandrogen monotherapy need to be
monitored for PSA progression and often need to be switched
to another antiandrogen because of side effects.
Most studies examining the role of hormone therapy
for localized prostate cancer have included patients with
clinical stage T3 tumors [19, 20]. Our data represent
the first comparison between antiandrogen monotherapy
and LHRH agonists for clinical T1_2 prostate cancer.
Although our results are interesting, they are nonetheless
preliminary. Additional studies with larger sample sizes
are required before a definitive recommendation in favor
of LHRH agonist therapy in the treatment of localized
prostate cancer can be made.
References
1 Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F.
Response to flutamide withdrawal in advanced prostate
cancer in progression under combination therapy. J Urol 1993;
150: 908_13.
2 Labrie F, Cusan L, Gomez JL, Diamond P, Candas B.
Combination of screening and preoperative endocrine therapy: the
potential for an important decrease in prostate cancer mortality.
J Clin Endocrinol Metab 1995; 80: 2002_13.
3 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics
1998. CA Cancer J Clin 1998; 48: 6_29.
4 Benoit RM, Naslund MJ. The socioeconomic implications of
prostate-specific antigen screening. Urol Clin North Am 1997;
24: 451_8.
5 Fakas A, Schneider D, Perrotti M, Cummings KB, Ward WS.
National trends in the epidemiology of prostate cancer, in
1973 to 1994: evidence for the effectiveness of
prostate-specific antigen screening. Urology 1998; 52: 444_8.
6 Gardner P, Hudson BL. Advance Report of Final Mortality
Statistics, 1993. Monthly Vital Statistics Report, vol 44 (7)
Suppl 29. Maryland: U. S. Department of Health and Human
Services, Center for Disease Control and Prevention/National
Center for Health Statistics; 1996.
7 Huggins C, Stevens RE, Hodges CV. Studies on prostatic
cancer. II. The effects of castration on advanced carcinoma of
the prostate. Arch Surg 1941; 43: 209_23.
8 Bagshaw MA, Cox RS, Hancock SL. Control of
prostate cancer with radiotherapy: long-term results. J Urol 1994; 152:6. LHRH
agonist and antiandrogen therapy in localized prostate cancer
1781_5.
9 Hodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson
J, Jones GW, et al. Results of conservative management of
clinically localized prostate cancer. N Engl J Med 1994; 330:
242_8.
10 Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in
clinically localised prostatic carcinoma. Br J Urol 1992; 69:
183_7.
11 Chen C, Poulin R, Labrie F. Large Shionogi tumors lose their
responsiveness to flutamide treatment. J Steroid Biochem Mol
Biol 1996; 58: 489_94.
12 Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long
term survival among men with conservatively treated
localized prostate cancer. JAMA 1995; 274: 626_31.
13 Schellhammer PF, Sharifi R, Block N, Soloway M, Venner P,
Patterson AL, et al. A controlled trial of bicalutamide versus
flutamide, each in combination with lutinizing
hormone-releasing hormone analogue therapy, in patients with advanced
prostate cancer. Casodex Combination Study Group. Urology
1995; 45: 745_52.
14 Chodak GW. Leutinizing hormone-releasing hormone releasing
hormone agonists for treatment of avanced prostate carcinoma.
Urology 1989; 33: 42_4.
15 Iversen P. Quality of life issues relating to endocrine treatment
options. Eur Urol 1999; 36 (Suppl) 2: 20_6.
16 Delaere KP, Van Thillo EL. Flutamide monotherapy as
primary treatment in advanced prostatic carcinoma. Semin Oncol
1991; 18: 13_8.
17 Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM.
Long-term efficacy and safety of nilutamide plus castration in
advanced prostate cancer, and the significance of early
prostate specific antigen normalization. International Anandron
Study Group. J Urol 1997; 158: 160_3.
18 Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L,
Tammela T, et al. A randomized comparison of Casodex
(bicalutamide) 150 mg monotherapy versus castration in the
treatment of metastatic and locally advanced prostate cancer.
Eur Urol 1998; 33: 447_56.
19 Schellhammer P, Lynch D. Are monotherapy options reasonable
for T3 prostate cancer? Semin Urol Oncol 1997; 15: 207_14.
20 Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel
H, Tammela TL, et al. Bicalutamide monotherapy compared
with castration in patients with nonmetastatic locally advanced
prostate cancer: 6.3 years of followup. J Urol 2000; 164:
1579_82. |